We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · January 18, 2022

Final Overall Survival and Molecular Analysis in IMmotion151

JAMA Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
JAMA Oncol 2021 Dec 23;[EPub Ahead of Print], RJ Motzer, T Powles, MB Atkins, B Escudier, DF McDermott, BY Alekseev, JL Lee, C Suarez, D Stroyakovskiy, U De Giorgi, F Donskov, B Mellado, R Banchereau, H Hamidi, O Khan, V Craine, M Huseni, N Flinn, S Dubey, BI Rini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading